ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Second-Generation CML Drugs Show Promise For Frontline

December 26, 2008

Support For Translational Researchers Urgently Needed, ASCO President Says

May 22, 1998

NCI AIDS Malignancy Bank Accepts Requests; RFA Available

December 1, 1995

NCI-Approved Clinical Trials Listed For Month Of March

April 27, 2001

FDA Approves BMS’s Yervoy For Metastatic Melanoma

March 25, 2011

Funding Opportunities: PAs Available.

January 28, 2005